ONC201 + nivolumab

ONC201 + nivolumab is a combination therapy that pairs two distinct anti-cancer agents. ONC201 (also known as TIC10 or dordaviprone) is a small molecule that inactivates AKT and ERK signaling pathways and activates the TRAIL pathway. It acts as a selective antagonist of dopamine receptor D2 (DRD2) and as an allosteric agonist of mitochondrial protease caseinolytic protease P (ClpP). Nivolumab (marketed as Opdivo) is an immune checkpoint inhibitor that targets PD-1 (programmed cell death protein 1). The combination was investigated to potentially overcome resistance to immune checkpoint inhibitors in microsatellite stable colorectal cancer, which typically does not respond to immunotherapy alone.

Other names

ONC201 plus nivolumabONC-201 plus nivolumabONC 201 plus nivolumab